The offering includes ordinary shares, pre-funded warrants and warrants

Davis Polk advised the placement agents in connection with a multi-tranche private placement of ordinary shares, pre-funded warrants and warrants of Inventiva S.A. The immediately available proceeds of the private placement are €94.1 million and up to an additional €253.9 million may be raised, for a total offering size of €348 million, subject to the satisfaction of specified conditions. Inventiva’s ordinary shares are listed on Euronext Paris under the symbol “IVA”, and its ADSs are listed on the Nasdaq Global Market under the same symbol.

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH, and other diseases with significant unmet medical needs.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Kerim K. Aksoy. Partner David R. Bauer and associates Francesca Masella and Lizzy Pott provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post